Klotho Neurosciences (KLTO) Stock Price, News & Analysis

Company Overview

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.

Key Stats

• Today's Range: $0.58 to $0.72
• 50-Day Range: $0.45 to $0.90
• 52-Week Range: $0.11 to $3.91
• Volume: 3.12 million shs
• Average Volume: 14.51 million shs
• Market Capitalization: $43.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Klotho Neurosciences Stock Analysis - MarketRank™

Klotho Neurosciences scored higher than 11% of companies evaluated by MarketBeat, and ranked 919th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Klotho Neurosciences.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Klotho Neurosciences is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Klotho Neurosciences is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Klotho Neurosciences has a P/B Ratio of 15.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.53% of the float of Klotho Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Klotho Neurosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Klotho Neurosciences has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Klotho Neurosciences does not currently pay a dividend.

Dividend Growth

Klotho Neurosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.53% of the float of Klotho Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

Klotho Neurosciences has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Klotho Neurosciences has recently increased by 33.33%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.95

News Sentiment

Klotho Neurosciences has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Klotho Neurosciences this week, compared to 1 article on an average week.

Search Interest

Only 7 people have searched for KLTO on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.

MarketBeat Follows

3 people have added Klotho Neurosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Klotho Neurosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.70% of the stock of Klotho Neurosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.07% of the stock of Klotho Neurosciences is held by institutions.

KLTO Stock Analysis - Frequently Asked Questions

How have KLTO shares performed this year?

Klotho Neurosciences' stock was trading at $0.4850 at the beginning of 2025. Since then, KLTO shares have increased by 27.5% and is now trading at $0.6186.

How were Klotho Neurosciences' earnings last quarter?

Klotho Neurosciences, Inc. (NASDAQ:KLTO) released its quarterly earnings results on Monday, August, 18th. The company reported ($0.12) earnings per share for the quarter.

How do I buy shares of Klotho Neurosciences?

Shares of KLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/18/2025
• Today: 10/16/2025
• Next Earnings (Estimated): 11/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KLTO
• Previous Symbol: NASDAQ:KLTO
• CIK: 1907223
• Web: www.klothoneuro.com
• Phone: (833) 931-6330
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$6.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -325.88%
• Return on Assets: -242.15%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 135.73
• Quick Ratio: 135.73

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.04 per share
• Price / Book: 16.50

Miscellaneous

• Outstanding Shares: 70,335,000
• Free Float: 51,556,000
• Market Cap: $46.41 million
• Optionable: N/A
• Beta: 10.05